Answers are grounded in this paper and cite their sources.
As the UK regulator reviews alteplase in ischaemic stroke, Brian Alper and colleagues interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours
No takes yet. Share an insight, caveat, or question.
Alper et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: